Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Bezlotoxumab

Catalog #:   DXX00301 Specific References (49) DATASHEET
Host species: Human
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DXX00301

Expression system

Mammalian Cells

Species reactivity

Clostridioides difficile

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Toxin B, 3.4.22.-, Glucosyltransferase TcdB, 2.4.1.-, tcdB, toxB

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P18177

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MK-6072, CDB-1, MDX-1388, MK-3415A (combination of actoxumab and bezlotoxumab), formerly CDB 1, CAS: 1246264-45-8

Clone ID

Bezlotoxumab

Data Image
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Development of a toxin-selective immunotracer for in vivo detection of Clostridioides difficile infection by immunoPET., PMID:40512279

Extended-pulsed fidaxomicin therapy for recurrent Clostridioides difficile infection after standard vancomycin and fidaxomicin failure: A case report., PMID:40250802

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan., PMID:40149040

Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection., PMID:40119029

Impact of adjunct bezlotoxumab for preventing Clostridioides difficile infection recurrence in patients post - hematopoietic stem cell transplantation., PMID:39865797

Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC)., PMID:39821840

Arrhythmic storm in a liver transplant recipient: Could bezlotoxumab be the trigger?, PMID:39701915

Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure of FMT Alone in the Treatment of Recurrent C. difficile Infection., PMID:39621384

[Evaluation of the management of Clostridioides difficile infection as a risk factor for recurrence. A retrospective observational study]., PMID:39588562

The always evolving diagnosis and management of Clostridioides difficile colitis: What you need to know., PMID:39509684

Microbiota restoration for recurrent Clostridioides difficile infection., PMID:39382853

[Clostridioides difficile infections: Update and therapeutic guidelines]., PMID:39377303

Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO study., PMID:39374859

Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience., PMID:39363592

Clostridioides difficile infection: an update., PMID:39282548

Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review., PMID:39281262

Diagnostic and therapeutic management of Clostridioides difficile infection., PMID:39271443

Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease., PMID:39230037

Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?, PMID:39141079

Treating Helicobacter pylori and Recurrent Clostridioides difficile Coinfection: A Delicate Balance in Management and a Need for Guidelines., PMID:38835648

Exploring the Toxin-Mediated Mechanisms in Clostridioides difficile Infection., PMID:38792835

Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies., PMID:38739837

Fighting against Clostridioides difficile infection: Current medications., PMID:38734214

Clostridioides Difficile: A Concise Review of Best Practices and Updates., PMID:38726585

Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection., PMID:38701911

Clostridioides difficile Colitis., PMID:38677819

Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection., PMID:38665169

New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation., PMID:38591915

Clostridioides difficile infection: a changing treatment paradigm., PMID:38571533

Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection., PMID:38546138

Enhancing bezlotoxumab binding to C. difficile toxin B2: insights from computational simulations and mutational analyses for antibody design., PMID:38511411

Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives., PMID:38508330

Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection., PMID:38501667

The management of Clostridioides difficile infection: from empirism to evidence., PMID:38344334

Structural and functional insight into the interaction of Clostridioides difficile toxin B and FZD7., PMID:38308843

Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence., PMID:38236366

European Practice for CDI Treatment., PMID:38175471

Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI., PMID:37931679

Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient., PMID:37787395

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI., PMID:37764005

Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review., PMID:37664309

Therapeutics for Clostridioides difficile infection: molecules and microbes., PMID:37606962

How Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center., PMID:37549387

Prevention and treatment of C. difficile in cancer patients., PMID:37527003

Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis., PMID:37395627

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)., PMID:37389891

Clostridium difficile in inflammatory bowel disease., PMID:37265220

[Clostridioides difficile - New Insights and Therapy Recommendations]., PMID:37257477

Clostridioides difficile Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis., PMID:37237740

Datasheet

Document Download

Research Grade Bezlotoxumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Bezlotoxumab [DXX00301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only